213 research outputs found
International Stock Market Efficiency: A Non-Bayesian Time-Varying Model Approach
This paper develops a non-Bayesian methodology to analyze the time-varying
structure of international linkages and market efficiency in G7 countries. We
consider a non-Bayesian time-varying vector autoregressive (TV-VAR) model, and
apply it to estimate the joint degree of market efficiency in the sense of Fama
(1970, 1991). Our empirical results provide a new perspective that the
international linkages and market efficiency change over time and that their
behaviors correspond well to historical events of the international financial
system.Comment: 21 pages, 2 tables, 6 figure
Oxaliplatin for Metastatic Colon Cancer in a Patient with Renal Failure
The efficacy, safety, pharmacokinetics, and dialysability of oxaliplatin were assessed in a hemodialysis patient with recurrent cecal cancer
Myosin motor Myo1c and its receptor NEMO/IKK-Ī³ promote TNF-Ī±āinduced serine307 phosphorylation of IRS-1
Tumor necrosis factor-Ī± (TNF-Ī±) signaling through the IĪŗB kinase (IKK) complex attenuates insulin action via the phosphorylation of insulin receptor substrate 1 (IRS-1) at Ser307. However, the precise molecular mechanism by which the IKK complex phosphorylates IRS-1 is unknown. In this study, we report nuclear factor ĪŗB essential modulator (NEMO)/IKK-Ī³ subunit accumulation in membrane ruffles followed by an interaction with IRS-1. This intracellular trafficking of NEMO requires insulin, an intact actin cytoskeletal network, and the motor protein Myo1c. Increased Myo1c expression enhanced the NEMOāIRS-1 interaction, which is essential for TNF-Ī±ā induced phosphorylation of Ser307āIRS-1. In contrast, dominant inhibitory Myo1c cargo domain expression diminished this interaction and inhibited IRS-1 phosphorylation. NEMO expression also enhanced TNF-Ī±āinduced Ser307āIRS-1 phosphorylation and inhibited glucose uptake. In contrast, a deletion mutant of NEMO lacking the IKK-Ī²ābinding domain or silencing NEMO blocked the TNF-Ī± signal. Thus, motor protein Myo1c and its receptor protein NEMO act cooperatively to form the IKKāIRS-1 complex and function in TNF-Ī±āinduced insulin resistance
Carcinosarcoma of the Sigmoid Colon: Report of a Case
Our case was a 65-year-old male, with the chief complaints of diarrhea and abdominal distention. Three years earlier, the patient had undergone transcatheter arterial embolization and radiofrequency treatment based on a diagnosis of hepatocellular carcinoma due to hepatitis B by another doctor. In October 2007, the patient developed diarrhea and increased abdominal distention. In December, CT examination conducted by the previous doctor revealed a 20-cm tumor within the pelvis. The patient was diagnosed with sigmoid colon cancer based on barium enema examination using gastrografin, and was introduced to our hospital for treatment. He was diagnosed with low-differentiated carcinoma by biopsy of the colon during endoscopy and underwent sigmoidectomy based on a diagnosis of sigmoid colon cancer. The tumor had infiltrated the bladder, and a tumorectomy was conducted through partially combined resection. The tumor was a huge lesion occupying the inside of the lumen, and histopathological findings revealed that the tumor, the main part of which lay beneath the mucous membrane, had a transitional image composed of both spindle-shaped atypical cells and sarcomatoid shape. The result of immunostaining was CK7(+), CK20(-), AFP(-), and the patient was diagnosed as having carcinosarcoma of the colon. Carcinosarcoma of the colon is a malignant tumor with poor prognosis, and the mean survival period in past reports was approximately 6 months. The patient was treated with FOLFIRI+Bevacizumab therapy according to chemotherapy for colon cancer, but he was refractory to the therapy
Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study
Introduction
Clinical data of esaxerenone in hypertensive patients with diabetic kidney disease (DKD) are lacking. We evaluated the efficacy and safety of esaxerenone in patients with DKD and an inadequate response to blood pressure (BP)-lowering treatment.
Methods
In this multicenter, open-label, prospective study, patients were divided into urinary albumin-to-creatinine ratio subcohorts (UACRā
Results
In total, 113 patients were enrolled. Morning home SBP/DBP significantly decreased from baseline to EOT in the total population (āā11.6/āā5.2 mmHg, both pā
Conclusion
Esaxerenone demonstrated a BP-lowering effect and improved albuminuria. The effects were consistent regardless of the severity of albuminuria without clinically relevant serum potassium elevation and eGFR reduction
- ā¦